MORE►
biopharma
Joe DePinto, head of cell, gene, and advanced therapies at McKesson [Composite photo; original: McKesson]
North Texas’ McKesson Launches InspiroGene to Support Commercialization of Cell and Gene Therapies
by Lance Murray | Oct 1, 2024
McKesson said that with a scalable, flexible suite of services and an experienced leadership team, InspiroGene enables manufacturers, payers, and providers to navigate the complex CGT commercialization landscape—ensuring that "patients can access the life-changing treatments they need."
by Kathleen Otto and George Goodno |
Mar 17, 2022
"When it comes to the biotech industry, our region is leading the U.S. in key metrics of job growth and investment," write Kathleen Otto and George Goodno. One proof point? VC funding is flowing into DFW at a faster rate than any other area in the nation.
These North Texas life science leaders say the region's success is no coincidence. Here's how the shared ambition of key players and strategic collaboration has impact.
These North Texas life science leaders say the region's success is no coincidence. Here's how the shared ambition of key players and strategic collaboration has impact.
MORE►
by Alex Edwards |
Oct 21, 2021
The funding, which was co-led by Pfizer Ventures and EcoR1 Capital, will help drive ReCode's therapy programs for primary ciliary dyskinesia and cystic fibrosis into human clinical studies.
MORE►
by Alex Edwards |
Nov 18, 2020
Lantern Pharma amassed 1 billion data points on its proprietary artificial intelligence platform, which it believes is the most of any company in biotech. Now, the company is able to reduce cost, time, and risk to establish a more sustainable route in oncology drug development.
MORE►
